Abstract The emergence of a sovereign mRNA therapeutic platform within The Russian Federation, specifically targeting advanced stage melanoma through personalized neoantigen recognition, represents a critical inflection point in the global biotechnological balance of power as of February 11, 2026. Under the direction of Alexander Gintsburg at the Gamaleya Center, the successful transition from the adenovirus-vector … Leggi tutto Strategic Implications of Sovereign mRNA Biotechnological Advancement and Therapeutic Oncological Research within the Russian Federation